EL7.AI
StocksMediumUpdated•Originally published 4 November 2026•Updated 5 November 2026•
1 min read

Caris Life Sciences Reports $275.4M Q3 Revenue and Raises Full-Year 2026 Guidance

Key Facts

1Caris Life Sciences reported Q3 revenue of $275.4 million, a 27% increase year-over-year.
2The company raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion.
3Clinical case volume reached approximately 61,500, consisting of over 358,000 total oncology tests during the quarter.

Caris Life Sciences reported revenue of $275.4 million for the third quarter of 2026, marking a 27% increase year-over-year. According to a statement released via PR Newswire, clinical case volume reached approximately 61,500, including over 358,000 total oncology tests during the period. Consequently, the company raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion.

CAI closed at $32.85 on November 3, 2026, with the stock reaching a session high of $34 and a low of $32.14. This financial growth was primarily driven by strong performance in molecular profiling services and increased testing volumes within the oncology sector.

Latest Updates · 1

  1. Notable·

    Update: Caris Life Sciences reported third-quarter earnings per share of $0.05, surpassing analyst estimates of $0.03. Despite the earnings beat, CAI shares declined in after-hours trading following the announcement.

Open on chart